Three hundred seventy patients with upper or lower urinary tract infections were entered into a multicenter, open comparative study. A total of 190 patients were treated with norfloxacin, and 180 patients were treated with trimethoprim-sulfamethoxazole. The percentage of strains susceptible to norfloxacin (99%) was significantly greater (P < 0.001) than the percentage of strains susceptible to trimethoprim-sulfamethoxazole (90%). The percentages of patients with bacteriological outcomes of eradication were greater in the norfloxacin group (97%) than in the trimethoprim-sulfamethoxazole group (90%). The difference was significant (P < 0.05). Seven patients (three treated with norfloxacin, four treated with trimethoprim-sulfamethoxazole) experienced early reinfection. Of 370 patients entered into the study, 20 patients experienced clinical adverse effects that were probably or definitely related to the study drug; 6 patients were in the group that received norfloxacin, and 14 were in the group that received trimethoprim-sulfamethoxazole. Study antimicrobial agents were discontinued because of clinical adverse effects in eight patients (norfloxacin, one patient; trimethoprim-sulfamethoxazole, seven patients). Three patients receiving norfloxacin and four patients receiving trimethoprimsulfamethoxazole had laboratory adverse effects which were classified as probably or definitely drug related.
Norfloxacin (NOR) is a quinoline carboxylic acid derivative with excellent in vitro activity (90% MIC . 0.5 ,ug/ml) against members of the family Enterobacteriaceae associated with urinary tract infections (UTI). This includes organisms such as Escherichia coli, Klebsiella-Enterobacter spp., indole-positive and indole-negative Proteus spp., Morganella morganii, and Citrobacter spp. that are both susceptible and resistant to the commonly used oral antimicrobial agents. NOR is also active (90% MIC = 1.0 to 8.0 ,ug/ml) against Serratia marcescens, Providencia spp., Pseudomonas aeruginosa, Streptococcus faecalis and Staphylococcus saprophyticus (4, 6, 8, (13) (14) (15) . In addition, NOR has proven activity against multiresistant bacteria (3) . Activity against anaerobic bacteria is not significant (9) . Other important features are low spontaneous mutation rates and a lack of cross-resistance with nalidixic acid (4) .
Single-dose studies reveal that 400 mg of NOR administered orally produced mean concentrations in serum of 1.58 ,ug/ml with a mean serum half-life between 3.5 and 4.0 h. In healthy volunteers, urinary concentrations are approximately 100 times that in serum (17) . Within 24 h, approximately 30% of a single oral dose can be recovered from the urine, and six metabolites of NOR have been identified in human urine (16) . More than 70% of NOR is excreted as unaltered drug (16, 17) .
The objectives of this multiclinic study were to compare the efficacy, safety, and tolerability of NOR with that of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of UTI.
MATERIALS AND METHODS Nineteen investigators in 11 countries participated in this study (Table 1) . Three hundred seventy patients with UTI entered the open, randomized, controlled study. Informed consent was obtained from each patient. Patients were numbered consecutively in the order of acceptance into the study and assigned to treatment by a randomized allocation schedule. Excluded from entering the study were patients with * Corresponding author. allergic diathesis, any serious systemic disease or concomitant infection, or severe functional or urological abnormalities, i.e., nephrolithiasis, neurogenic bladder. After completing diagnostic evaluation, either NOR, at a dose of 400 mg twice daily, or TMP-SMX, at a dose of 160/800 mg twice daily, was given orally.
Urine cultures to evaluate efficacy and blood specimens for laboratory evaluation of hematological, renal, and hepatic safety parameters were requested for each patient before and during therapy (days 2 to 4) and 5 to 9 days posttherapy. Also, specimens were obtained for urinalysis, including microscopic examination, to determine the presence or absence of drug crystals. A final urine culture was obtained late (4 to 6 weeks) posttherapy. Bacteriological outcomes for pathogens isolated at pretreatment were evaluated during and after therapy or at the time of discontinuation of therapy.
A patient was classified as suitable for efficacy evaluation (i.e., evaluable) if all of the following criteria were satisfied: (i) Pretreatment urine culture exhibited a bacteriological colony count 2105/ml; whenever possible, antibody-coated bacteria (ACB) testing was performed. Investigators used any of three ACB test methods described previously (5, 7, 18) . (ii) The clinical diagnosis was clearly defined as UTI. (iii) The patient had not received effective antimicrobial therapy within 72 h before initiation of study drug therapy. (iv) The patient had not received other antimicrobial agent therapy concomitantly. This did not apply to patients receiving other antimicrobial agent therapy after study drug therapy had been deemed a failure. (v) The duration of study drug therapy was adequate, i.e., for patients with cystitis 3 days or longer, and for those with upper UTI, 7 days of treatment or longer. (vi) Adequate follow-up bacteriological urine cultures were obtained both during and after therapy.
The bacteriological outcome was defined as follows. Eradication was indicated by negative follow-up urine cultures during and posttherapy. Suppression was defined by a negative urine culture during therapy and a positive culture posttherapy. Persistence was indicated by a positive urine culture during therapy. Both suppression and persistence ,ug/ml for TMP-SMX.
Differences in in vitro susceptibility were analyzed by testing for marginal homogeneity, and differences in efficacy were determined by a Mantel-Haenszel procedure (11) . The Fischer Exact Test was used to compare the effects of the two drugs within pathogen type (10) .
Patients in the NOR and TMP-SMX treatment groups were assessed to determine the similarity of demographic, clinical, and laboratory variables. Data from all patients were analyzed for safety. For statistical purposes, comparisons were made using all patients that entered the study and those evaluable patients who had pathogens susceptible to both study drugs. In addition, bacteriological outcome was determined in a subset of patients, irrespective of drug susceptibility of the initial pathogen, and in those patients with pathogens susceptible to the study drug received, but not necessarily to the other drug.
RESULTS
Patients. Of 370 patients that entered into the study (NOR, 190 patients; TMP-SMX, 180 patients), 226 patients were evaluable and had bacteria susceptible to both study drugs (NOR, 101 patients; TMP-SMX, 125 patients). Analysis revealed that patients were similar with respect to age, incidence of secondary diagnoses, incidence of prior therapy, incidence of signs and symptoms of UTI, and mean values of all laboratory safety values. A greater number of males were entered into the study in the NOR group (50 of 190) compared with the TMP-SMX group (32 of 180). The difference is borderline significant (P = 0.06). This unequal distribution of male patients disappeared when the analysis was done only on those patients with pathogens susceptible to both study drugs (Table 2) .
In Vitro activity. NOR proved to have a broader spectrum of in vitro activity than TMP-SMX. Seven patients (NOR, three patients; TMP-SMX, four patients) experienced early reinfection detected during therapy or within 1 week of discontinuation of study drug. Follow-up urine cultures at late times posttherapy were obtained in 183 evaluable patients. Of these, four patients in the group that received NOR and seven patients in the group that received TMP-SMX had late relapses. All four patients receiving NOR and five patients receiving TMP-SMX had a history of two or more episodes of UTI. The rates of late relapse were not significantly different between the two treatment groups. Most relapses were due to E. coli. Serotyping was not available; thus, the possibility of reinfection with different strains of E. coli was not excluded. Three NOR-treated patients and three TMP-SMX-treated patients experienced late reinfection with a bacterium different from that isolated in the pretreatment culture. All of these patients had a history of previous UTI.
Safety. Of 370 patients entered into the study, 20 patients experienced clinical adverse effects that were probably or definitely related to the study drug; 6 patients were in the group that received NOR and 14 patients were in the group that received TMP-SMX. None of the effects was serious. Table 5 lists adverse effects; some patients had more than one adverse effect (NOR, 11 patients; TMP-SMX, 16 patients). Most adverse effects were manifested in the gastrointestinal system. One patient (0.5%) in the group receiving NOR and seven patients (3.9%) in the group receiving TMP-SMX were discontinued from the study because of clinical adverse effects. The difference (3.4%) is significant (P = 0.04). A patient in the group receiving NOR experienced abdominal cramps. Four patients in the group receiving TMP-SMX had gastrointestinal adverse effects, and three patients had rash.
Three patients that received NOR and four patients that received TMP-SMX had laboratory adverse effects which were classified as probably or definitely drug related. None was serious. Some patients had more than one reaction, including (patients receiving NOR/patients receiving TMP-SMX): decreased leukocyte count (1/3), decreased neutrophils (3/1), decreased platelet count (0/1), increased lymphocytes (1/0), increased blood urea nitrogen (0/1), and increased serum creatinine (0/1).
Drug crystalluria (NOR or sulfa) was not observed in microscopic examination of urinary sediments. The mean baseline creatinine level in serum in the group receiving NOR was 84 mmol/liter; during therapy the level was 86 mmol/liter; this difference is not significant. The mean baseline serum creatinine level in the group receiving TMP-SMX was 79 mmol/liter; during therapy the level was 91 mmol/liter; this difference is significant (P < 0.01). The difference in between group mean changes in creatinine levels in serum is also significant (P < 0.01). DISCUSSION NOR has a wide spectrum of antimicrobial activity against both the common and uncommon bacteria implicated in UTI. The superior in vitro antimicrobial spectrum of NOR was evident in this multicenter study in which 99% of the strains isolated with known susceptibilities were susceptible to NOR and only 90% were susceptible to TMP-SMX.
Analysis of the similarity for all patients revealed that a greater proportion of TMP-SMX-resistant strains occurred in the group receiving NOR than in the group receiving TMP-SMX. Also, there was a trend of more male patients in the group receiving NOR than in the group receiving TMP-SMX. These two findings suggest that the randomized allocation schedule appears not to have been followed strictly in some cases in which bacteria had known resistance to TMP-SMX. Most likely some of these patients were allocated to the group receiving NOR. However, the initial efficacy analysis included only patients with bacteria susceptible to both study drugs; thus, bias in relation to drug susceptibility is excluded. As a consequence of this, the trend toward unequal distribution of male patients disappeared in this specific category of patients ( Table 2) .
The efficacy data were also analyzed separately for all evaluable patients (regardless of drug susceptibility) and for patients with pathogens susceptible to the study drug (but not to the other drug). This last category permitted analysis of patients with UTI caused by bacteria resistant to commonly used antibiotics, such as Pseudomonas aeruginosa, for which NOR could be better therapy than TMP-SMX. Urinary tract infections due to resistant bacteria such as Pseudomonas aeruginosa, Klebsiella-Enterobacter spp., and indole-positive Proteus spp. are usually associated with complicated UTIs and lower rates of eradication of bacteriuria. Moreover, the resistance pattern of the bacteria isolated was an important indicator of the comparability or noncomparability of the treatment groups. Because of the broader in vitro spectrum of activity of NOR compared with TMP-SMX, the results are biased against NOR in this category. In spite of this, a greater percentage of patients treated with NOR had a bacteriological outcome of eradication than those treated with TMP-SMX (95% versus 91%, respectively); however, this difference was not significant. When patients were classified irrespective of the initial susceptibility of the bacteria to the study drug, the effectiveness of NOR was significantly better (P < 0.05) than that of TMP-SMX. These results could have been predicted because of the broader in vitro activity of NOR than that of TMP-SMX. However, because of the greater proportion of TMP-SMX-resistant strains in the group receiving NOR than in the group receiving TMP-SMX, the difference may be even greater than that which was found.
The ABC test was used to classify UTI as upper or lower. It is a useful and noninvasive test (7, 18) ; however, its sensitivity and specificity have been questioned (12) . Efficacy rates for patients with upper UTI (ACB positive) were no different than the eradication rate obtained in patients with unclassified UTI (ACB negative) for both study drugs.
The safety profile of NOR was similar to that of TMP-SMX. However, based on the incidence of withdrawal from the study because of clinical adverse effects, NOR was better tolerated than was TMP-SMX (NOR, 1 patient; TMP-SMX, 7 patients; P < 0.05). No serious clinical adverse experiences were related to either study drug.
The mean value and the increase from baseline of the creatinine level observed in serum in the group receiving TMP-SMX could suggest the possibility of a better safety margin for NOR. However, a rise in the creatinine level in serum after trimethoprim administration has been described previously; it appears to be due to the competitive effect between trimethoprim and creatinine for tubular secretion. The effect is reversible, and glomerular filtration rates remain unchanged when measured with radioisotopes (2).
In conclusion, NOR has in vitro antimicrobial activity that is superior to that of TMP-SMX against both the common and uncommon bacteria implicated in UTI. NOR is more efficacious than TMP-SMX in the treatment of UTI. NOR has a good safety profile and is well tolerated at oral doses of 400 mg twice daily.
